Dataset opportunity
Pan Biotech — 监管记录数据集机会
Pan Biotech 持有的中等规模监管记录数据集,可用于监管 RAG 和合规性助手。
Score
68.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管事务 AI 市场 = 2024 年为 13.1 亿美元,复合年增长率为 18.60%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高(专有)
Accessibility
部分
Legal
公司所有 — 可授权
Buyer persona
监管科技与合规 AI 供应商
Pan Biotech 持有文本模态的监管记录数据集,包含丰富的工业数据、GMP 生产日志和监管申报的知识库。该专业语料库结构化,可立即用于监管 RAG 应用,使 AI 买家能够训练模型,从而加速合规性检查、优化申报策略并从复杂的监管文件中提取关键信息。
商业价值巨大,位于全球监管事务 AI 市场内,该市场在 2024 年的价值为13.1 亿美元,预计将以 18.60% 的复合年增长率增长。虽然访问需要应对专有知识产权和数据完整性审计的复杂性,但该数据集在缩短审批时间线和降低合规风险方面的价值,为生命科学领域的 AI 开发人员提供了引人注目的投资回报。⚠ 尽职调查(有价值的数据,可协商访问):专有介质配方是核心知识产权;GMP 生产日志需要严格的数据完整性审计;研发数据集可能与特定的细胞系性能相关 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Pan Biotech 拥有一项专有数据集,详细说明了生物技术制造在国际标准下的严格合规和质量控制流程。数据包括来自稳定性研究和无菌测试的纵向记录,这些对于ISO 9001 和 ISO 13485 认证至关重要。对于监管科技和合规 AI 供应商而言,这是培训复杂的监管 RAG 系统的稀有、高价值资产。收购这些数据可直接进入快速扩张的 13.1 亿美元监管事务 AI 市场,该市场正以每年超过 18% 的速度增长。
See dimension details ↓- Dataset Specificity78
主导的“监管”,医疗保健行业,2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI 买家需求旺盛,这得益于全球监管事务 AI 市场的快速增长,该市场正以 18.60% 的复合年增长率扩张。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility50
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License92
所有权=公司所有,授权=干净
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号(0 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — PAN-Biotech 是一个绝佳的目标,因为它是一家德国中小型细胞培养产品制造商,其生产过程会产生大量的专有监管、制造和质量控制数据作为副产品,并且没有证据表明他们目前正在销售这些数据。问题:与一家名称相似的实体“Pan.bio”存在潜在的利益冲突,该实体明确销售真实患者数据;必须小心区分
- Deep Qualification90
⚠ 需要审查 — PAN-Biotech 是一个潜在的监管和制造日志的数据持有者,但由于其 CDMO 服务,数据所有权是混合的,并且其数据集与细分市场中指定的药物开发数据不完全一致。[实体不持有细分市场的特征数据:目标是制造材料(例如细胞培养基)的供应商,而不是药物开发者;它拥有其自身产品和流程的监管数据,但没有最终药品或药物疗效报告的临床试验数据。]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
该公司从其GMP 认证的生产线生成详细日志,捕获环境和质量控制参数,这些参数对于流程优化和审计 AI 工具很有价值。
Knowledge base / docs
这是一个专有知识库,包含大量的研发数据,记录了数百种细胞培养基配方的性能,为监管申报提供了深入的科学背景。
Regulatory records
这些证据包括来自稳定性研究和无菌测试的纵向记录,这些对于在医疗器械和生物技术领域保持ISO 13485 和 ISO 9001 合规性至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Pan Biotech Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in Regulatory Affairs Market = $1.31B in 2024, CAGR 18.60% (source: Grand View Research). Investment score 68.4/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Coleintl — 法规记录数据集机会
View opportunity →出行Independentlogistics — 监管记录数据集机会
View opportunity →交通运输Hartmann International — API 可访问数据集机会
View opportunity →